Sanofi SA

As of June 30, 2026, Sanofi carries a market capitalization of 101.44B, placing it among publicly traded companies globally. Its enterprise value stands at 121.53B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Sanofi has 1.21B shares outstanding.

As of June 30, 2026, Sanofi trades at a trailing price-to-earnings ratio of 22.32. The price-to-sales ratio is 1.81, and the price-to-book ratio stands at 1.28.

As of June 30, 2026, Sanofi trades at an EV/EBITDA multiple of 13.57 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.49 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sanofi trades at an EV/FCF ratio of 8.57, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 121.53B versus a market cap of 101.44B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sanofi maintains a current ratio of 0.99, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.89, indicating elevated leverage, while an interest coverage ratio of 10.74 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sanofi posted a return on equity (ROE) of 5.69, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 4.79 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.82, useful for judging operating efficiency across full business cycles. The company generates approximately 711,802.83 in revenue per employee across its workforce of 78,516.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.79 indicates how many times Sanofi sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sanofi recorded 1.37B in income tax expense. That works out to an effective tax rate of 22.14, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 6.21B, leaving 4.52B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sanofi's stock has declined approximately 18.19% over the past 52 weeks. The 50-day moving average sits at 84.05, while the 200-day moving average is 90.49.

Over the twelve months ended June 30, 2026, Sanofi generated 55.89B in revenue and converted that into 4.52B in net income, yielding earnings per share of 3.78. EBITDA reached 8.96B, while operating income came in at 11.50B.

As of June 30, 2026, Sanofi holds 7.25B in cash and equivalents against 26.93B in total debt, resulting in a net debt position of 17.50B. Total book value stands at 79.07B, with working capital of -466.13M providing operational flexibility.

Sanofi produced 13.52B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sanofi posted a gross margin of 72.77, reflecting its pricing power and cost economics. The operating margin of 20.58 and net profit margin of 8.09 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 13.40, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sanofi shareholders.

Sanofi's most recent stock split took place on May 24, 1999 with a 1:4 split ratio.